The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls.
Open accessAbstract
The human hepatitis B virus (HBV) HBx protein is a small transcriptional activator that is essential for virus infection. HBx is thought to be involved in viral hepatocarcinogenesis because it promotes tumorigenesis in transgenic mice. HBx activates the RAS-RAF-mitogen-activated protein (MAP) kinase signaling cascade, through which it activates transcription factors AP-1 and NF-kappa B, and stimulates cell DNA synthesis. We show that HBx stimulates cell cycle progression, shortening the emergence of cells from quiescence (G0) and entry into S phase by at least 12 h, and accelerating transit through checkpoint controls at G0/G1 and G2/M. Compared with serum stimulation, HBx was found to strongly increase the rate and level of activation of the cyclin-dependent kinases CDK2 and CDC2, and their respective active association with cyclins E and A or cyclin B. HBx is also shown to override or greatly reduce serum dependence for cell cycle activation. Both HBx and serum were found to require activation of RAS to stimulate cell cycling, but only HBx could shorten checkpoint intervals. HBx therefore stimulates cell proliferation by activating RAS and a second unknown effector, which may be related to its reported ability to induce prolonged activation of JUN or to interact with cellular p53 protein. These data suggest a molecular mechanism by which HBx likely contributes to viral carcinogenesis. By deregulating checkpoint controls, HBx could participate in the selection of cells that are genetically unstable, some of which would accumulate unrepaired transforming mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
HBx gene of hepatitis B virus induces liver cancer in transgenic mice
Kim, C.-M., Koike, K., Saito, I., Miyamura, T., & Jay, G. (1991) · Nature · doi:10.1038/351317a0 · Cited by 1,158
THE MOLECULAR BIOLOGY OF THE HEPATITIS B VIRUSES
Ganem, D., & Varmus, H. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003251 · Cited by 1,084
Formation and Activation of a Cyclin E-cdk2 Complex During the G 1 Phase of the Human Cell Cycle
Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J. W., Elledge, S., Nishimoto, T., Morgan, D. O., Franza, B. R., & Roberts, J. M. (1992) · Science · doi:10.1126/science.1388288 · Cited by 1,043
Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
Chisari, F. V., Klopchin, K., Moriyama, T., Pasquinelli, C., Dunsford, H. A., Sell, S., Pinkert, C. A., Brinster, R. L., & Palmiter, R. D. (1989) · Cell · doi:10.1016/0092-8674(89)90770-8 · Cited by 697
Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., & Harris, C. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2230 · Cited by 665
HBV X Protein Alters the DNA Binding Specificity of CREB and ATF-2 by Protein-Protein Interactions
Maguire, H. F., Hoeffler, J. P., & Siddiqui, A. (1991) · Science · doi:10.1126/science.1827531 · Cited by 454
Woodchuck hepatitis virus X protein is required for viral infection in vivo
Zoulim, F., Saputelli, J., & Seeger, C. (1994) · Journal of Virology · doi:10.1128/jvi.68.3.2026-2030.1994 · Cited by 453
Benn, J., & Schneider, R. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10350 · Cited by 418
Self-citationThe woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks
Chen, H. S., Kaneko, S., Girones, R., Anderson, R. W., Hornbuckle, W. E., Tennant, B. C., Cote, P. J., Gerin, J. L., Purcell, R. H., & Miller, R. H. (1993) · Journal of Virology · doi:10.1128/jvi.67.3.1218-1226.1993 · Cited by 370
Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway
Kekulé, A. S., Lauer, U., Weiss, L., Luber, B., & Hofschneider, P. H. (1993) · Nature · doi:10.1038/361742a0 · Cited by 369
trans-activation of viral enhancers by the hepatitis B virus X protein
Spandau, D. F., & Lee, C. H. (1988) · Journal of Virology · doi:10.1128/jvi.62.2.427-434.1988 · Cited by 315
High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice
Koike, K., Moriya, K., Iino, S., Yotsuyanagi, H., Endo, Y., Miyamura, T., & Kurokawa, K. (1994) · Hepatology · doi:10.1002/hep.1840190403 · Cited by 287
Dulić, V, Drullinger, L. F., Lees, E., Reed, S. I., & Stein, G. H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11034 · Cited by 279
Truant, R., Antunovic, J., Greenblatt, J., Prives, C., & Cromlish, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.3.1851-1859.1995 · Cited by 255
Seto, E., Yen, T. S., Peterlin, B. M., & Ou, J. H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.21.8286 · Cited by 208
Hepatitis B virus transactivator protein X interacts with the TATA-binding protein.
Qadri, I., Maguire, H. F., & Siddiqui, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.1003 · Cited by 185
Shirakata, Y., Kawada, M., Fujiki, Y., Sano, H., Oda, M., Yaginuma, K., Kobayashi, M., & Koike, K. (1989) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1989.tb01686.x · Cited by 170
The hepatitis B virus X-gene product trans-activates both RNA polymerase II and III promoters.
Aufiero, B., & Schneider, R. J. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08136.x · Cited by 159
Self-citationCross, J. C., Wen, P., & Rutter, W. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8078 · Cited by 156
Natoli, G., Avantaggiati, M. L., Chirillo, P., Costanzo, A., Artini, M., Balsano, C., & Levrero, M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.989 · Cited by 144
Balsano, C., Avantaggiati, M. L., Natoli, G., Marzio, E. D., Will, H., Perricaudet, M., & Levrero, M. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)90379-l · Cited by 118
The X protein of hepatitis B virus coactivates potent activation domains
Haviv, I., Vaizel, D., & Shaul, Y. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.1079 · Cited by 93
Association of casein kinase II with immunopurified p53.
HERRMANN, C., Kraiss, S., & Montenarh, M. (1991) · PubMed · Cited by 82
Guilhot, S., Fowler, P., Portillo, G., Margolskee, R. F., Ferrari, C. I., Bertoletti, A., & Chisari, F. V. (1992) · Journal of Virology · doi:10.1128/jvi.66.5.2670-2678.1992 · Cited by 65
Cited by
Schafer, K. A. (1998) · Veterinary Pathology · doi:10.1177/030098589803500601 · Cited by 604
The Enigmatic X Gene of Hepatitis B Virus
Bouchard, M. J., & Schneider, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.12725-12734.2004 · Cited by 498
Self-citationAbrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene
Wang, X. W. (2003) · Hepatocellular Carcinoma · doi:10.1385/1-59259-079-9:57 · Cited by 321
Waris, G., Huh, K.-W., & Siddiqui, A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.22.7721-7730.2001 · Cited by 318
Kim, S.-J., Khan, M., Quan, J., Till, A., Subramani, S., & Siddiqui, A. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003722 · Cited by 317
Metadata
- Authors
- Benn, J., & Schneider, R. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-11-21
- Volume
- 92
- Issue
- 24
- Pages
- 11215-11219
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2032781689
- Cited by
- 288
- References
- 27
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.